Trials / Completed
CompletedNCT03654170
A Study in Healthy Men to Find Out How BI 425809 is Taken up and Handled by the Body
Metabolism and Pharmacokinetics of BI 425809 After Administration of BI 425809 (C-14) as Oral Solution in Healthy Male Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- Male
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This trial intends to investigate the basic pharmacokinetics of BI 425809 and \[14C\]- radioactivity, including mass balance, excretion pathways and metabolism following a single oral dose of 25 mg BI 425809 (C-14) given to healthy male subjects
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BI 425809 mixed with [C-14] BI425809 | Single oral dose of 25 milligram (mg) mixture of Carbon 14 labelled \[14C\] BI 425809 XX, containing a radioactive dose of 3.7 MegaBecquerel (MBq), and unlabeled BI 425809 XX dissolved in 12.5 milliliter (mL) polyethylene glycol 400 (PEG) as solvent. |
Timeline
- Start date
- 2018-09-11
- Primary completion
- 2018-11-12
- Completion
- 2018-11-12
- First posted
- 2018-08-31
- Last updated
- 2026-03-27
- Results posted
- 2026-03-27
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT03654170. Inclusion in this directory is not an endorsement.